Cuestiones controvertidas en evaluación económica (I): Perspectiva y costes de intervenciones sanitarias = Controversial issues in economic evaluation (I): Perspective and costs of health care interventions

Autor: Oliva, J.; Brosa, M.; Espin, J.; Figueras, M.; Trapero, M.; Antoñanzas Villar, Fernando Jesús; Delgado, J.; Gutierrez, R.; Labeaga, J.M.; Lobo, F.; Lopez Bastida, J.; Rivera, B.; 

Tipo de documento: Artículo de revista

Revista: Revista Española de Salud Pública. ISSN: 1135-5727. Año: 2015. Número: 1. Volumen: 89. Páginas: 5-14.

Texto completo open access 

SCIMAGO (datos correspondientes al año 2014):
SJR:
,237  SNIP: ,549 

CARHUS Plus+: B

CIRC: GRUPO A

Referencias:

  • Oliva, J., Antoñanzas, F., Rivero-Arias, O., Evaluación económica y la toma de decisiones en salud. El papel de la evaluación económica en la adopción y difusión de tecnologías sanitarias. Informe SESPAS 2008 (2008) Gac Sanit, 22, pp. 137-142
  • Drummond, M., Jönsson, B., Rutten, F., The role of economic evaluation in the pricing and reimbursement of medicines (1997) Health Policy, 40 (3), pp. 199-215
  • OECD, (2010) Value for Money in Health Spending, , París: OECD
  • Paris, V., Belloni, A., Value in pharmaceutical pricing (2013) OECD Health Working Papers, (63)
  • Puig-Junoy, J., Peiró, S., De la utilidad de los medicamentos al valor terapéutico añadido y a la relación coste-efectividad incremental (2009) Rev Esp Salud Pública, 83, pp. 59-70
  • Grossman, M., On the concept of health capital and the demand for health (1972) J Political Econ, 80 (2), pp. 223-255
  • Grossman, M., The human capital model of the demand for health (2000) Handbook of Health Economics, , AJ. Culyer and JP Newhouse (eds.). North-Holland
  • Koopmanschap, M.A., Van Ineveld, B.M., Towards a new approach for estimating indirect costs of disease (1992) Soc Sci Med, 34, pp. 1005-1010
  • Liljas, B., How to calculate indirect costs in economic evaluation (1998) Pharmacoeconomics, 13, pp. 1-7
  • Krol, M., Brouwer, W., Rutten, F., Productivity costs in economic evaluations: Past, present, future (2013) Pharmacoeconomics, 31, pp. 537-544
  • Lensberg, B.R., Drummond, M.F., Danchenko, N., Despiégel, N., François, C., Challenges in measuring and valuing productivity costs, and their relevance in mood disorders (2013) Clinicoecon Outcomes Res, 18 (5), pp. 565-573
  • Oliva, J., Lobo, F., Lopez-Bastida, J., Zozaya, N., Romay, R., Indirect costs of cervical and breast cancer in Spain (2005) Eur. J. Health Econ., 6, pp. 309-313
  • Hutubessy, R.C., Van Tulder, M.W., Vondeling, H., Bouter, L.M., Indirect costs of back pain in the Netherlands: A comparison of the human capital method with the friction cost method (1999) Pain, 80, pp. 201-207
  • Lofland, J.H., Lock Lear, J.C., Frick, K.D., Different approaches to valuing the lost productivity of patients with migraine (2001) Pharmacoeconomics, 19, pp. 917-925
  • Marcotte, D.E., Wilcox-Gok, V., Estimating the employment and earnings costs of mental illness: Recent developments in the United States (2001) Soc Sci Med, 53, pp. 21-27
  • Van Den Berg, B., Brouwer, W., Koopmanschap, M., Economic valuation of informal care: An overview of methods and applications (2004) Eur J Health Econ, 5, pp. 36-45
  • Van Den Berg, B., Brouwer, W., Van Exel, J., Koopmanschap, M., Van Den Bos, G.A., Rutten, F., Economic evaluation of informal care: Lessons from the application of the opportunity costs and proxy good methods (2006) Soc Sci Med, 62 (4), pp. 835-845
  • De Meijer, C., Brouwer, W., Koopmanschap, M., Van Den Berg, B., Van Exel, J., The value of informal care - A further investigation of the feasibility of contingent valuation in informal caregivers (2010) Health Econ, 19 (7), pp. 755-771
  • Hoefman, R.J., Van Exel, J., Brouwer, W., How to include informal care in economic evaluations (2013) Pharmacoeconomics, 31 (12), pp. 1105-1119
  • Schnelle, E., The metaplan method. Communication tools for planning and learning groups (1979) Metaplan Series No. 7, , Hamburg: Quickborn
  • Johannesson, M., Jönsson, B., Jönsson, L., Kobelt, G., Zethreaus, N., Why should economic evaluations of medical technologies have a societal perspective? (2009) OHE Briefing Paper, , London: Office of Health Economics
  • Jönsson, B., Ten arguments for a societal perspective in the economic evaluation of medical innovations (2009) Eur J Health Econ, 10 (4), pp. 357-359. , Oct
  • LFN, TLV, (2003) General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board, , http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf, Solna: The Pharmaceutical Benefits Board
  • College voor zorgverzekeringen (CVZ), (2006) Guidelines for Pharmacoeconomic Research in the Netherlands, , http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/publications-in-english/2006/0604-guidelines-for-pharmacoeconomic-research/0604-guidelines-for-pharmacoeconomic-research/Guidelines+for+pharmacoeconomic+research.pdf, Diemen: CVZ
  • Cleemput, I., Neyt, M., Van De Sande, S., Thiry, N., (2012) Belgian Guidelines for Economic Evaluations and Budget Impact Analyses: Second Edition, , Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Report 183C. D/2012/10.273/54
  • National Institute for Health and Care (NICE), (2013) Guide to the Methods of Technology Appraisals, , http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf, London: NICE
  • Canadian Agency for Drugs and Technologies in Health (2006) Guidelines for the Economic Evaluation of Health Technologies: Canada [3rd Edition], , Ottawa:Canadian Agency for Drugs and Technologies in Health
  • Institut für Qualität Wirtschaftlichkeit im Gesundheitswesen (IQWiG), (2009) General Methods for the Assessment of the Relation of Benefits to Costs, , https://www.iqwig.de/download/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf, (Version 1.0 dated 19/11/2009). Colonia: IQWiG
  • Department of Health and Ageing, (2008) Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (Version 4.3), , Canberra: Australian Government
  • López-Bastida, J., Oliva, J., Antoñanzas, F., García, A., Gisbert, A., Mar, J., Puig-Junoy, J., Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias (2010) Gac Sanit, 24 (2), pp. 154-170
  • Sculpher, M.J., Pang, F.S., Manca, A., Drummond, M.F., Golder, S., Urdahl, H., Davies, L.M., Eastwood, A., Generalisability in economic evaluation studies in healthcare: A review and case studies (2004) Health Technol Assess, 8 (49), pp. iii-iv. , Dec
  • 1-192
  • Raikou, M., Briggs, A., Gray, A., McGuire, A., Centre-specific or average unit costs in multi-centre studies? Some theory and simulation (2000) Health Econ, 9 (3), pp. 191-198. , Apr
  • Adam, T., Evans, D.B., Determinants of variation in the cost of inpatient stays versus outpatient visits in hospitals: A multi-country analysis (2006) Soc Sci Med, 63 (7), pp. 1700-1710. , Oct
  • Antoñanzas, F., Rodríguez-Ibeas, R., Juárez, C., Hutter, F., Lorente, R., Pinillos, M., Transferability indices for health economic evaluations: Methods and applications (2009) Health Econ, 18 (6), pp. 629-643. , Jun
  • Puig-Junoy, J., Oliva-Moreno, J., Trapero-Bertran, M., Abellán-Perpiñán, J.M., Brosa-Riestra, M., (2014) Guía y Recomendaciones para la Realización y Presentación de Evaluaciones Económicas y Análisis de Impacto Presupuestario de Medicamentos en el Ámbito del CatSalut (Versión Preliminar para Consulta Pública), , Barcelona: Servei Català de la Salut (CatSalut)
  • Puig-Junoy, J., Oliva, J., Evaluación económica de intervenciones sanitarias: El coste de oportunidad de no evaluar (2009) Reumatol Clín, 5 (6), pp. 241-243
  • Artells, J.J., Peiró, S., Meneu, R., Barreras a la introducción de una agencia evaluadora para informar la financiación o la desinversión de prestaciones sanitarias del Sistema Nacional de Salud (2014) Rev Esp Salud Pública, 88 (2), pp. 217-231
  • Asociación de Economía de la Salud, (2013) Sistema Nacional de Salud: Diagnóstico y Propuestas de Avance, , Barcelona: Asociación de Economía de la Salud
  • National Health Service-England-and Monitor, The NHS Payment System: Documents and Guidance, , https://www.gov.uk/government/collections/the-nhs-payment-system-regulating-prices-for-nhs-funded-healthcare, Citado el 10 de junio de 2014
  • Nicholson, S., Pauly, M.V., Polsky, D., Sharda, C., Szrek, H., Berger, M.L., Measuring the effects of work loss on productivity with team production (2006) Health Econ, 15, pp. 111-123
  • Tilling, C., Krol, M., Tsuchiya, A., Brazier, J., Brouwer, W., In or out? Income losses in health state valuations: A review (2010) Value Health, 13 (2), pp. 298-305. , Mar-Apr
  • Nyman, J.A., Productivity costs revisited: Toward a new US policy (2012) Health Econ, 21, pp. 1387-1401
  • Peña Longobardo, L.M., Oliva, J., Economic Valuation and Determinants of Informal Care to People with Alzheimer's Disease, , accepted for publication in The European Journal of Health Economics
  • Garrido, S., Abellán, J.M., Sánchez, F.I., Valoración monetaria de los cuidados informales a partir de la disposición a aceptar de cuidadores y no cuidadores (2013) XXXIII Jornadas de Economía de la Salud, , 18-21 de junio de 2013. Santander: Asociación de Economía de la Salud